SkyePharma Thoughts Turn To M&A And In-House Research After Financial Turnaround
This article was originally published in Scrip
With increasing revenues and profits the UK drug delivery firm SkyePharma could only dream of some years ago, CEO Peter Grant says he will consider investing in internal research and external M&A opportunities, in a measured way, to build a long-term product pipeline.
You may also be interested in...
Laura Soucek, one of In Vivo’s 2020 Rising Leaders, is hoping to take Barcelona-based start-up Peptomyc to the next level. The company is nearing the clinic with an inhibitor of the transcription factor Myc, which is involved in the regulation of cellular proliferation, but can also be a driver of cancer.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
With a candidate COVID-19 therapy in clinical development, the UK’s Synairgen has raised $101m on the UK’s AIM to support clinical studies and manufacturing plans.